March 4, 2020 11:05 AM ESTUpdated 11:44 AM
Financing

Can re­for­mu­la­tion of an As­traZeneca castoff ri­val Takeda's new heart­burn drug? Here's a $26M bet on yes

Amber Tong

Linaprazan didn’t make much of a mark at As­traZeneca. De­spite show­ing promise in ear­ly-stage stud­ies, the potas­si­um com­pet­i­tive acid block­er, or PCA-B,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times